No Routine Laboratory Monitoring Required
For healthy women taking levonorgestrel/ethinyl estradiol combined oral contraceptives, routine laboratory monitoring is not necessary. Blood pressure measurement is the only essential clinical parameter that requires monitoring 1.
What Monitoring IS Required
Blood Pressure Only
- Blood pressure assessment is the sole mandatory monitoring parameter for combined hormonal contraceptive users 1
- Should be checked before initiation and at routine follow-up visits
- Can be obtained in non-clinical settings (pharmacy, fire station) if healthcare access is limited 1
- Women with systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg should not use combined hormonal contraceptives 1
Optional Baseline Measurements
- Weight/BMI: Not required for medical eligibility, but may be useful for monitoring changes over time 1
- This helps counsel women concerned about weight changes perceived to be associated with their contraceptive method
What Laboratory Tests Are NOT Needed
The following tests do not contribute substantially to safe and effective use and are classified as "Class C" (not necessary) 1:
- Glucose testing - not required even though diabetic women have restrictions on combined hormonal contraceptive use
- Lipid panels - unnecessary despite potential effects on lipid metabolism 2
- Liver enzymes - not needed routinely
- Hemoglobin - not required
- Thrombogenic mutation screening - specifically not recommended for routine screening 2
- Cervical cytology (Pap smear) - does not affect contraceptive safety
- STD/HIV screening - does not impact contraceptive eligibility
- Clinical breast examination - not necessary before prescribing 1, 3
- Bimanual/pelvic examination - not required 1, 3
Follow-Up Recommendations
No routine follow-up visit is required after initiating combined hormonal contraceptives 1. However, at other routine visits, providers should:
- Assess satisfaction with the contraceptive method
- Assess any changes in health status or medications that would change appropriateness of continued use
- Reassess blood pressure
- Consider assessing weight changes if the patient has concerns
When to Return
Advise women to return at any time to discuss:
- Side effects or problems
- Desire to change methods
Special Populations Requiring More Frequent Monitoring
While healthy women need minimal monitoring, more frequent follow-up may benefit 1:
- Adolescents
- Women with certain medical conditions or characteristics
- Women with multiple medical conditions
Important Caveats
Thrombophilia Screening Exception
The only circumstance requiring laboratory investigation is when there is a first-degree family history of thromboembolic events before age 60 2. In this specific case, testing should include:
- Prothrombin time (PT)
- Activated partial thromboplastin time (aPTT)
- Antithrombin, protein C, protein S levels
- Factor V Leiden
- Prothrombin (FII) 20210A
Drug Interaction Considerations
While not routine laboratory monitoring, be aware that the FDA label notes potential interactions requiring clinical vigilance 4:
- Hepatitis C drug combinations (contraindicated with certain regimens)
- Strong CYP3A4 inducers (rifampin, certain anticonvulsants)
- Lamotrigine (may require dose adjustment)
The evidence consistently demonstrates that requiring prerequisite laboratory tests introduces unnecessary barriers to contraceptive care 3. The focus should remain on blood pressure measurement and clinical assessment rather than routine laboratory monitoring.